ALEC vs PRTA vs IONS vs RCUS

For growth investors, Ionis Pharmaceuticals, Inc.

(IONS) is the stronger pick with 33. 9% revenue growth year-over-year, versus -92. 8% for Prothena Corporation plc (PRTA). Analysts rate Alector, Inc. (ALEC) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Ionis Pharmaceuticals, Inc.

(IONS) delivered a total return of +108. 0%, compared to -85. 1% for Alector, Inc. (ALEC). Over 10 years, the gap is even starker: IONS returned +121. 1% versus ALEC's -86. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Ionis Pharmaceuticals, Inc.

(IONS) is the lower-risk stock at 0. 55β versus Alector, Inc. 's 2. 47β — meaning ALEC is approximately 353% more volatile than IONS relative to the S&P 500. On balance sheet safety, Prothena Corporation plc (PRTA) carries a lower debt/equity ratio of 5% versus 5% for Ionis Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Ionis Pharmaceuticals, Inc.

(IONS) is pulling ahead at 33. 9% versus -92. 8% for Prothena Corporation plc (PRTA). On earnings-per-share growth, the picture is similar: Ionis Pharmaceuticals, Inc. grew EPS 21. 7% year-over-year, compared to -99. 6% for Prothena Corporation plc. Over a 3-year CAGR, RCUS leads at 30. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Ionis Pharmaceuticals, Inc.

(IONS) is the more profitable company, earning -40. 4% net margin versus -25. 2% for Prothena Corporation plc — meaning it keeps -40. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IONS leads at -40. 5% versus -1905. 8% for PRTA. At the gross margin level — before operating expenses — IONS leads at 98. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for PRTA: 80.

4% to $19. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Ionis Pharmaceuticals, Inc.

(IONS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 55), +121. 1% 10Y return). Alector, Inc. (ALEC) carries a higher beta of 2. 47 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (IONS: +121. 1%, ALEC: -86. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ALEC is a small-cap quality compounder stock; PRTA is a small-cap quality compounder stock; IONS is a mid-cap high-growth stock; RCUS is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.